Payment overview · 2025
General Payments
$659.51
31 reported records · 11 companies
Healthcare provider profile · identity verified
Thomas A Johnson, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BROOKFIELD, WI · NPI 1891762852
Verified facts
What the public records show
CMS Open Payments records show Thomas A Johnson, MD received $659.51 in general payments during 2025 across 31 reported records.
Amgen Inc. accounted for 23.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic, Shingrix.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 242 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 242 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $152.10 | 23.1% | 8 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $89.62 | 13.6% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $83.46 | 12.7% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $67.12 | 10.2% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $54.73 | 8.3% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $49.89 | 7.6% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $45.87 | 7.0% | 2 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $41.65 | 6.3% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $30.22 | 4.6% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.76 | 3.6% | 1 | 2025 |
| BeOne Medicines USA, Inc. | Unresolved — no canonical attribution shown | $21.09 | 3.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $659.51 | 31 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $76.73 | 4 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $69.23 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $53.26 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $50.05 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $50.05 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $50.05 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $49.89 | 2 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $46.30 | 2 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $41.65 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $36.28 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $36.28 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $30.84 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $30.22 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $23.76 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $21.66 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $21.66 | 1 | 2025 |
Source payment records
|
|||||
| BRUKINSA Normalized: brukinsa |
Drug | BeOne Medicines USA, Inc. | $21.09 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $20.73 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.85 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $17.42 | 1 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $7.95 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 242 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 125 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 36 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
125 | 38 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
242 | 51 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
36 | 34 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
242 | 51 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1284 | 375 |
| Irbesartan | Irbesartan | 867 | 245 |
| Amlodipine Besylate | Amlodipine Besylate | 697 | 209 |
| Levothyroxine Sodium | Levothyroxine Sodium | 487 | 124 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 307 | 99 |
| Omeprazole | Omeprazole | 299 | 89 |
| Metformin Hcl Er | Metformin Hcl | 289 | 80 |
| Pantoprazole Sodium | Pantoprazole Sodium | 276 | 84 |
| Carvedilol | Carvedilol | 273 | 85 |
| Metoprolol Succinate | Metoprolol Succinate | 264 | 79 |
| Ezetimibe | Ezetimibe | 253 | 73 |
| Lisinopril | Lisinopril | 251 | 87 |
| Eliquis | Apixaban | 242 | 51 |
| Furosemide | Furosemide | 240 | 78 |
| Allopurinol | Allopurinol | 224 | 63 |
| Tamsulosin Hcl | Tamsulosin Hcl | 203 | 60 |
| Sertraline Hcl | Sertraline Hcl | 192 | 55 |
| Tramadol Hcl | Tramadol Hcl | 175 | 54 |
| Trazodone Hcl | Trazodone Hcl | 173 | 55 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 159 | 51 |
| Losartan Potassium | Losartan Potassium | 158 | 50 |
| Potassium Chloride | Potassium Chloride | 158 | 40 |
| Gabapentin | Gabapentin | 153 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 152 | 55 |
| Lorazepam | Lorazepam | 145 | 44 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 127 | 127 |
| Jardiance | Empagliflozin | 125 | 38 |
| Alprazolam | Alprazolam | 119 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 114 | 32 |
| Alendronate Sodium | Alendronate Sodium | 105 | 32 |
| Zolpidem Tartrate | Zolpidem Tartrate | 105 | 35 |
| Escitalopram Oxalate | Escitalopram Oxalate | 104 | 32 |
| Metformin Hcl | Metformin Hcl | 102 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 100 | 32 |
| Doxazosin Mesylate | Doxazosin Mesylate | 96 | 27 |
| Glimepiride | Glimepiride | 94 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 90 | 26 |
| Hydralazine Hcl | Hydralazine Hcl | 89 | 24 |
| Atenolol | Atenolol | 86 | 24 |
| Clonidine Hcl | Clonidine Hcl | 86 | 25 |
| Memantine Hcl | Memantine Hcl | 82 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 77 | 22 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 77 | 32 |
| Januvia | Sitagliptin Phosphate | 69 | 12 |
| Warfarin Sodium | Warfarin Sodium | 68 | 14 |
| Meloxicam | Meloxicam | 65 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 64 | 19 |
| Celecoxib | Celecoxib | 57 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 56 | 15 |
| Clonazepam | Clonazepam | 54 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 53 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 53 | 16 |
| Donepezil Hcl | Donepezil Hcl | 52 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 51 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 43 | 26 |
| Ozempic | Semaglutide | 43 | suppressed |
| Spironolactone | Spironolactone | 43 | 12 |
| Simvastatin | Simvastatin | 42 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 41 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 41 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 41 | 16 |
| Cephalexin | Cephalexin | 39 | 35 |
| Sumatriptan Succinate | Sumatriptan Succinate | 37 | suppressed |
| Azithromycin | Azithromycin | 36 | 31 |
| Myrbetriq | Mirabegron | 36 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 36 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 35 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 35 | 14 |
| Propranolol Hcl | Propranolol Hcl | 33 | 13 |
| Cefuroxime | Cefuroxime Axetil | 31 | 29 |
| Mirtazapine | Mirtazapine | 31 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 31 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Synthroid | Levothyroxine Sodium | 31 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 30 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 29 | 27 |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 26 | suppressed |
| Famotidine | Famotidine | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Finasteride | Finasteride | 25 | 11 |
| Klor-Con 10 | Potassium Chloride | 25 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Gemtesa | Vibegron | 22 | suppressed |
| Lansoprazole | Lansoprazole | 22 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | 15 |
| Betamethasone Valerate | Betamethasone Valerate | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 18 |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 19 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 18 | suppressed |
| Cholestyramine Light | Cholestyramine | 18 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | 13 |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Prednisone | Prednisone | 17 | 11 |
| Valsartan | Valsartan | 17 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | 11 |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Febuxostat | Febuxostat | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Tegretol Xr | Carbamazepine | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Epinephrine | Epinephrine | 11 | suppressed |
| Klor-Con M10 | Potassium Chloride | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $659.51 · 31 records | Amgen Inc. | ABRYSVO, BRUKINSA, CAMZYOS, COMIRNATY, Cologuard Collection Kit, ELIQUIS, EVENITY, JARDIANCE, JOURNAVX, KRYSTEXXA, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, PROLIA, REPATHA, Rybelsus, SHINGRIX, TEPEZZA, VOQUEZNA, Wegovy | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error